Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

At the 2019 International Aspirin Foundation Scientific Conference 'Benefits and Risks of Antithrombotic Therapy for Cardiovascular Disease Prevention', held in Rome, Italy, international experts sought to discuss and debate the optimal antithrombotic strategy for the secondary prevention of cardiovascular disease (CVD) and to seek agreement around dosing and target populations for aspirin use in primary disease prevention. Getting the best evidence to support real-life decisions in the clinic can be complex, and individualising management in order to balance both the risks and benefits of different disease prevention strategies appears to be the best approach. It is hoped that future decision-making tools and biomarkers will help direct treatments at those most likely to benefit.

Original publication

DOI

10.3332/ecancer.2020.998

Type

Presentation

Publication Date

2020

Volume

14

Keywords

anticoagulant, antiplatelet, antithrombotic, aspirin, benefit, cardiovascular disease (CVD), colorectal cancer (CRC), diabetes mellitus (DM), gastroprotectant agents, optimizing aspirin dose, precision medicine, primary prevention, risk, secondary prevention, targeting, upper gastrointestinal (GI) bleeding